Lymphoid Malignancies clinical trials at UCLA
1 research study open to eligible people
Showing trials for
OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
open to eligible people ages 12-95
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Lymphoid Malignancies research studies include Gary Schiller, MD.
Last updated: